Redmile Group’s PTC Therapeutics PTCT Stock Holding History

Redmile Group’s Portfolio PTCT Stock Details PTCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-859,526	Closed	-$41.3M	–	75
2019 Q4	$41.3M	Buy	+859,526	New	+$36.5M	0.99%	29

Other funds holding PTCT

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Redmile Group's PTCT Position: Q1 2020 in Review

Redmile Group sold out of PTC Therapeutics (PTCT) in Q1 2020, closing a stake of 859,526 shares — an estimated $41.3M sold.

Redmile Group first reported a position in PTCT in Q4 2019 and held it in 1 quarter. The position peaked at $41.3M in Q4 2019. 202 funds tracked by Wall St. Rank hold PTCT as of Q1 2020.

Redmile Group reported no remaining PTC Therapeutics position as of Q1 2020 after selling out during the quarter.
Redmile Group sold 859,526 PTC Therapeutics shares in Q1 2020, an estimated $41.3M.
Redmile Group first reported a position in PTC Therapeutics in Q4 2019 and held it in 1 quarter.
Redmile Group's PTC Therapeutics position peaked at $41.3M in Q4 2019.
202 funds tracked by Wall St. Rank held PTC Therapeutics as of Q1 2020.

Based on Redmile Group's 13F filing for Q1 2020, filed 15 May 2020.